Edition:
United States

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

11.03USD
26 May 2017
Change (% chg)

$0.73 (+7.09%)
Prev Close
$10.30
Open
$10.27
Day's High
$11.29
Day's Low
$10.24
Volume
345,052
Avg. Vol
236,734
52-wk High
$12.22
52-wk Low
$4.05

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix presents additional phase 3 data results for Dextenza
Monday, 8 May 2017 08:00am EDT 

May 8 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix presents additional phase 3 data and patient reported outcomes results for Dextenza at the American Society of Cataract and Refractive Surgery (ASCRS) symposium.Says U.S. FDA has set a target action date under prescription drug user fee act (PDUFA) of July 19, 2017.There were no treatment-related serious adverse events (SAES) and Dextenza was well tolerated in all clinical trials.PDUFA date of July 19, 2017 for decision regarding potential approval of Dextenza for treatment of ocular pain following ophthalmic surgery.Subject to approval of NDA for post-surgical ocular pain by FDA, Ocular Therapeutix intends to submit supplement to NDA for Dextenza.No patients experienced any adverse events resulting in study withdrawal.  Full Article

Ocular Therapeutix reports Q1 loss per share of $0.58
Friday, 5 May 2017 07:30am EDT 

May 5 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports first quarter 2017 financial results.Q1 loss per share $0.58.Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.Generated $0.5 million in revenue during three-month period ended March 31, 2017 from product sales of Resure sealant.  Full Article

Ocular Therapeutix appoints George Migausky interim CFO
Thursday, 6 Apr 2017 08:00am EDT 

Ocular Therapeutix Inc - : Ocular Therapeutix appoints George Migausky as interim chief financial officer . Company continues to evaluate candidates for permanent cfo role .Migausky replaces brad smith who recently relinquished his role as cfo at company.  Full Article

Ocular Therapeutix- Bradford Smith notified on march 20 of his resignation from his position as CFO, effective March 31, 2017
Monday, 20 Mar 2017 04:54pm EDT 

Ocular Therapeutix Inc : Ocular Therapeutix- Bradford Smith notified on March 20 of his resignation from his position as CFO of company, effective march 31, 2017 - sec filing .Ocular Therapeutix- Co's coo, will assume roles of principal financial officer, principal accounting officer on interim basis, effective April 1, 2017.  Full Article

Ocular Therapeutix announced positive results of patient experience study of Dextenza
Wednesday, 15 Mar 2017 08:00am EDT 

Ocular Therapeutix Inc : Ocular Therapeutix Inc - announced positive results of patient experience study of dextenza (dexamethasone insert) 0.4 mg for intracanalicular use . Nda for dextenza is currently under review by fda for treatment of ocular pain occurring after ophthalmic surgery . Fda has set a pdufa target action date for july 19, 2017 . Ocular therapeutix - intends to submit an nda supplement for dextenza to broaden its label to include a post-surgical inflammation indication .All patients reported that intracanalicular insert was comfortable.  Full Article

Ocular Therapeutix Q4 loss per share $0.52
Friday, 10 Mar 2017 07:30am EST 

Ocular Therapeutix Inc : Ocular Therapeutix(tm) reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.52 . Q4 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S . Qtrly total revenue $511,000 versus $436,000 . Ocular Therapeutix Inc - as of december 31, 2016, cash, cash equivalents and marketable securities totaled $68.1 million .Will need to obtain additional capital to support planned commercial launch of dextenza, subject to fda approval.  Full Article

Ocular Therapeutix NDA resubmission for dextenza accepted by FDA
Wednesday, 22 Feb 2017 08:00am EST 

Ocular Therapeutix Inc : Ocular Therapeutix announces FDA acceptance of NDA resubmission for dextenza for the treatment of ocular pain occurring after ophthalmic surgery .Ocular Therapeutix Inc - target action date under prescription drug user fee act of July 19, 2017 for potential approval of dextenza.  Full Article

Ocular Therapeutix Inc announces pricing of public offering of common stock
Tuesday, 24 Jan 2017 08:00am EST 

Ocular Therapeutix Inc : Ocular Therapeutix Inc announces pricing of public offering of common stock .Ocular Therapeutix Inc says pricing of a public offering of 3.6 million shares of its common stock at a public offering price of $7.00 per share.  Full Article

Ocular Therapeutix continues to prepare for resubmission to NDA for Dextenza
Wednesday, 14 Dec 2016 04:42pm EST 

Ocular Therapeutix Inc : Continued to prepare for resubmission to NDA for DEXTENZA that co previously filed in Sept 2015 -SEC filing . NDA resubmission is expected early in Q1 of 2017 following completion of testing of these commercial batches .Plan is to include manufacturing records from recently completed commercial batches of Dextenza in NDA resubmission -SEC filing.  Full Article

Ocular Therapeutix entered into a controlled equity offering sales agreement
Wednesday, 30 Nov 2016 06:05am EST 

Ocular Therapeutix Inc : On Nov 29, co entered into a controlled equity offering sales agreement - SEC filing .Under agreement,Co may offer,sell shares of common stock,$0.0001 par value / earnings per share,having aggregate offering price of up to $40 million.  Full Article

More From Around the Web

BRIEF-Ocular Therapeutix presents additional phase 3 data results for Dextenza

* Ocular Therapeutix presents additional phase 3 data and patient reported outcomes results for Dextenza at the American Society of Cataract and Refractive Surgery (ASCRS) symposium